To address the national shortage of surgical oncology clinician-investigators, the Department of Surgical Oncology at the University of Texas M. D. Anderson Cancer Center has dedicated its T32 training program to producing academic surgical oncologists. This goal is being met by developing in our T32 trainees the research background skills necessary to be a productive surgical investigator. Moreover, we are committed to providing T32 training to groups that are underrepresented in academic surgical oncology, including minority individuals and women. Our T32 program provides research opportunities in a broad range of basic oncologic disciplines, including tumor biology, oncogene and tumor suppressor gene biology, signal therapeutics and other cancer-related research areas. In addition, we recently reincorporated the option for T32 fellows to obtain training in """"""""clinical effectiveness"""""""" while still obtaining didactic training in basic science research. This training broadens the education of all trainees through our conference structure. This versatility in academic training increases the likelihood of obtaining an academic position upon completion of training. Training in biostatistics and the responsible conduct of research, and a rich array of seminars and graduate courses are integral to this T32 program. Training is offered to postdoctoral M.D. fellows either during a 24-month hiatus from General Surgery residency or during a two to three-year fellowship in Surgical Oncology that begins after General Surgery residency. Upon completion of training almost all (94%) T32 trainees have either entered Surgical Oncology fellowships or geographic full time academic Surgical Oncology positions. The T32 program faculty includes surgical investigators and full-time academic basic science researchers, all of whom have peer-reviewed grant support. The University of Texas M. D. Anderson Cancer Center vigorously promulgates a core mission excellence in research, education, and patient care. As a result, this is a highly stimulating environment in which aspiring academic surgical oncologists can receive research training under the aegis of the T32 program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009599-23
Application #
8020130
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
1994-05-25
Project End
2013-01-31
Budget Start
2011-02-01
Budget End
2012-01-31
Support Year
23
Fiscal Year
2011
Total Cost
$424,044
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Surgery
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Kim, B J; Day, R W; Davis, C H et al. (2017) Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective. J Thromb Haemost 15:2158-2164
Roife, David; Kang, Ya'an; Wang, Li et al. (2017) Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. Surgery 161:1246-1254
Gall, Victor A; Philips, Anne V; Qiao, Na et al. (2017) Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Res 77:5374-5383
Arango, Natalia Paez; Brusco, Lauren; Mills Shaw, Kenna R et al. (2017) A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget 8:41806-41814
Voss, Rachel K; Chiang, Yi-Ju; Torres, Keila E et al. (2017) Adherence to National Comprehensive Cancer Network Guidelines is Associated with Improved Survival for Patients with Stage 2A and Stages 2B and 3 Extremity and Superficial Trunk Soft Tissue Sarcoma. Ann Surg Oncol 24:3271-3278
Dai, Bingbing; Roife, David; Kang, Ya'an et al. (2017) Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther 16:662-670
Reuben, Alexandre; Spencer, Christine N; Prieto, Peter A et al. (2017) Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2:
Patel, Sameer H; Kim, Bradford J; Tzeng, Ching-Wei D et al. (2017) Reduction of Cardiopulmonary/Renal Complications with Serum BNP-Guided Volume Status Management in Posthepatectomy Patients. J Gastrointest Surg :
Voss, Rachel K; Feng, Lei; Lee, Jeffrey E et al. (2017) Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. J Clin Endocrinol Metab 102:2807-2813
Evans, Kurt W; Yuca, Erkan; Akcakanat, Argun et al. (2017) A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res 23:6468-6477

Showing the most recent 10 out of 177 publications